Dumayo, William B.

HRN: 09-87-17  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/21/2022
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
10/21/2022
10/25/2022
IVT
2.25g
Q8
UTI; CAP MR
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Urinary TractPneumonia    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: